BCL2 and acute lymphoblastic leukemia: The combination of Ruxolitinib and GSK-LSD1 was further tested for its efficiency to reverse the expression of anti- and pro-apoptotic proteins (BCL2 & BIM) in Zeb2Tg ETP-ALL.